Interventional Oncology Global Market – Forecast to 2026

Publishing Date : March, 2020
Report Code : HCMD0168
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Interventional Oncology (I.O.) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, and other cancers. Rather than removing tumors through open surgical procedures, these image-guided procedures can be performed in place of or in combination with other cancer treatments to provide truly comprehensive care. The advantage of these methods is that I.O. has much less effect on the body compared to conventional procedures.

An estimated by IQ4I Research, the interventional oncology global market is expected to grow a high single digit CAGR from 2019 to 2026 to reach $2,119.4 million by 2026. Some of the factors driving the market are increasing prevalence of cancer cases, growing adoption of minimally invasive procedures, increasing geriatric population, technological advancements in the field of interventional oncology, and expansion in the emerging markets.

The interventional oncology market by product is segmented as ablation and embolization. The embolization segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The ablation segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.

Ablation global market by product type, it is segmented into radiofrequency ablation, microwave ablation, cryoablation and others (irreversible electroporation and MRI-guided laser ablation). Among ablation, microwave ablation holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The other segment is the fastest-growing segment with a high double digit CAGR from 2019 to 2026. Embolization global market by product type, it is segmented into Radio-embolization and non-radioembolization. Among embolization, non-radioembolization holds the highest revenue in 2019 and it is expected to grow at a mid single digit CAGR from 2019 to 2026. The radio-embolization segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026. The embolization global market by procedure, it is segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), transcranial chemo-embolization (TACE), drug-eluting beads transcranial chemo-embolization (DEB-TACE) and transcranial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.

Interventional Oncology (I.O.) global market by application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, uterine fibroid and others. Among interventional oncology applications, the liver cancer segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The brain & spine cancer segment is the fastest-growing segment with a low double digit CAGR from 2019 to 2026.

Ablation global market by application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among ablation applications, the liver cancer segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The brain & spine cancer segment is the fastest-growing segment with a low double digit CAGR from 2019 to 2026. Embolization global market by application is segmented into liver cancer, lung cancer, prostate cancer, uterine fibroid and other. Among embolization applications, the liver cancer segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The uterine fibroid segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.

Interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), academics & research institutes. Among end-users, the hospital segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The ambulatory surgical center segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.

Interventional oncology market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, Japan, Australia and Rest of APAC) and Rest of the world (Brazil, Rest of LATAM and Middle East & Others). North America holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026 due to adoption of the technological advancements, increasing incidences of cancer, increased training institutes for interventional oncology, increasing demand for minimally invasive surgeries, favorable reimbursement, product launches, skilled personnel, and strong product pipeline. The Asia-Pacific region is the fastest-growing region with a low double digit CAGR from 2019 to 2026 due to increasing geriatric population, increased healthcare facilities, increasing incidence of cancer, increasing awareness about interventional oncology and low-cost for the surgery are driving the market.

The interventional oncology global market is a consolidated market with top 5 players occupying major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in interventional oncology market include Medtronic Plc (Ireland), Sirtex Medical (Australia), Boston Scientific Corporation (U.S.), Guerbet (France), Merit Medical System (U.S.), Varian Medical System, Inc. (U.S.), Terumo Corporation (Japan), Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • Australia
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of LATAM
  • Middle East and Others

     

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING PREVALENCE OF CANCER CASES
        • 3.3.1.2     GROWING ADOPTION OF MINIMALLY INVASIVE PROCEDURES
        • 3.3.1.3     INCREASING GERIATRIC POPULATION
        • 3.3.1.4     TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF INTERVENTIONAL ONCOLOGY
        • 3.3.1.5     EXPANSION IN THE EMERGING MARKETS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECTS AND RISKS ASSOCIATED WITH THE USE
        • 3.3.2.2     LACK OF AWARENESS AND UNDERSTANDING ABOUT INTERVENTIONAL ONCOLOGY IMPORTANCE
        • 3.3.2.3     LACK OF TRAINED PROFESSIONALS
        • 3.3.2.4     AVAILABILITY OF ALTERNATIVE TREATMENTS
        • 3.3.2.5     STRINGENT REGULATORY GUIDELINES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13485 MEDICAL DEVICES
        • 3.4.1.3     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
        • 3.4.1.4     ISO 14971 RISK MANAGEMENT OF MEDICAL DEVICES
        • 3.4.1.5     ISO 12807:2018 SAFE TRANSPORT OF RADIOACTIVE MATERIALS- LEAKAGE TESTING ON PACKAGES
        • 3.4.1.6     IEC 60601-1 MEDICAL ELECTRICAL EQUIPMENT STANDARD
        • 3.4.1.7     IEC 60601-1-2 ELECTROMAGNETIC COMPATIBILITY (EMC) FOR MEDICAL DEVICES
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     EUROPE
      • 3.4.5     JAPAN
      • 3.4.6     CHINA
      • 3.4.7     INDIA
    • 3.5     CLINICAL TRIALS DATA
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     REIMBURSEMENT SCENARIO
    • 3.9     REGULATORY APPROVED INTERVENTIONAL ONCOLOGY PRODUCTS BY COMPANY
    • 3.10     FUNDING SCENARIO
    • 3.11     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.11.1     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS
      • 3.11.2     ABLATION GLOBAL MARKET SHARE ANALYSIS
      • 3.11.3     EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS
    • 3.12     INTERVENTIONAL ONCOLOGY NUMBER OF UNITS BY REGION
      • 3.12.1     ABLATION DEVICES NUMBER OF UNITS BY REGION
      • 3.12.2     RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS BY REGION
      • 3.12.3     MICROWAVE ABLATION DEVICES NUMBER OF UNITS BY REGION
      • 3.12.4     CRYOABLATION DEVICES NUMBER OF UNITS BY REGION
    • 3.13     INTERVENTIONAL ONCOLOGY PROCEDURE VOLUME BY PRODUCT TYPE
    • 3.14     MARKET PENETRATION OF INTERVENTIONAL ONCOLOGY BY APPLICATION
    • 3.15     INTERVENTIONAL ONCOLOGY COMPANY COMPARISON TABLE BY REVENUE, PRODUCT AND APPLICATION
  • 4     INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     ABLATION
      • 4.2.1     RADIOFREQUENCY ABLATION
      • 4.2.2     MICROWAVE ABLATION
      • 4.2.3     CRYOABLATION ABLATION
      • 4.2.4     OTHER ABLATION
    • 4.3     EMBOLIZATION
      • 4.3.1     EMBOLIZATION BY PRODUCT TYPE
        • 4.3.1.1     RADIO-EMBOLIZATION
        • 4.3.1.2     NON-RADIOEMBOLIZATION
      • 4.3.2     EMBOLIZATION BY PROCEDURE
        • 4.3.2.1     TRANSARTERIAL RADIO-EMBOLIZATION (TARE)/ SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
        • 4.3.2.2     TRANSARTERIAL CHEMO-EMBOLIZATION (TACE)
        • 4.3.2.3     DRUG-ELUTING BEADS TRANSARTERIAL CHEMO-EMBOLIZATION (DEB-TACE)
        • 4.3.2.4     BLAND EMBOLIZATION/ TRANSARTERIAL EMBOLIZATION (TAE)
  • 5     INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
      • 5.1.1     LIVER CANCER
      • 5.1.2     KIDNEY CANCER
      • 5.1.3     LUNG CANCER
      • 5.1.4     BRAIN AND SPINE CANCER
      • 5.1.5     PROSTATE CANCER
      • 5.1.6     UTERINE FIBROIDS
      • 5.1.7     OTHER APPLICATIONS
  • 6     INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BY END-USERS
    • 6.1     INTRODUCTION
      • 6.1.1     HOSPITALS
      • 6.1.2     AMBULATORY SURGICAL CENTERS (ASC’S)
      • 6.1.3     ACADEMICS AND RESEARCH INSTITUTES
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     JAPAN
      • 7.4.3     AUSTRALIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST & OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     PRODUCT APPROVAL
    • 8.3     ACQUISITION AND PARTNERSHIP
    • 8.4     NEW PRODUCT LAUNCH
    • 8.5     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ANGIODYNAMICS INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     BOSTON SCIENTIFIC CORPORATION
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     GUERBET
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     JOHNSON & JOHNSON
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     MEDTRONIC PLC
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     MERIT MEDICAL SYSTEMS, INC.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     MONTERIS MEDICAL
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     SIRTEX MEDICAL LIMITED
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     TERUMO CORPORATION
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     VARIAN MEDICAL SYSTEM INC.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 2     ABLATION DEVICES NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 3     RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 4     MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 5     CRYOABLATION DEVICES NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
      • TABLE 6     ABLATION GLOBAL PROCEDURE VOLUME, BY PRODUCT TYPE, (2018-2026) (NO’S)
      • TABLE 7     EMBOLIZATION GLOBAL PROCEDURE VOLUME, BY PRODUCT TYPE, (2018-2026) (NO’S)
      • TABLE 8     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 9     ABLATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 10     ABLATION GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 11     RADIOFREQUENCY ABLATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 12     MICROWAVE ABLATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 13     CRYOABLATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 14     OTHER ABLATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 15     EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 16     EMBOLIZATION GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 17     RADIO-EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 18     NON-RADIOEMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 19     EMBOLIZATION GLOBAL MARKET REVENUE, BY PROCEDURE, (2018-2026) ($MN)
      • TABLE 20     TRANSARTERIAL RADIO-EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 21     TRANSARTERIAL CHEMO-EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 22     DEB-TACE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 23     TAE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 24     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 25     ABLATION GLOBAL MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 26     EMBOLIZATION GLOBAL MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 27     LIVER CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 28     LIVER CANCER ABLATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 29     LIVER CANCER EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 30     KIDNEY CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 31     LUNG CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 32     LUNG CANCER ABLATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 33     LUNG CANCER EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 34     BRAIN & SPINE CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 35     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 36     PROSTATE CANCER ABLATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 37     PROSTATE CANCER EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 38     UTERINE FIBROIDS GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 39     OTHER CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 40     OTHER CANCER ABLATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 41     OTHER CANCER EMBOLIZATION GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 42     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
      • TABLE 43     HOSPITALS GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 44     AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 45     ACADEMICS AND RESEARCH INSTITUES GLOBAL MARKET REVENUE, BY REGION, (2019-2026) ($MN)
      • TABLE 46     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 47     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 48     NORTH AMERICA ABLATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 49     NORTH AMERICA EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 50     NORTH AMERICA EMBOLIZATION MARKET REVENUE, BY PROCEDURE, (2018-2026) ($MN)
      • TABLE 51     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 52     NORTH AMERICA ABLATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 53     NORTH AMERICA EMBOLIZATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 54     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 55     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 56     EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 57     EUROPE ABLATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 58     EUROPE EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 59     EUROPE EMBOLIZATION MARKET REVENUE, BY PROCEDURE, (2018-2026) ($MN)
      • TABLE 60     EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 61     EUROPE ABLATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 62     EUROPE EMBOLIZATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 63     EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 64     EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 65     APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 66     APAC ABLATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 67     APAC EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 68     APAC EMBOLIZATION MARKET REVENUE, BY PROCEDURE, (2018-2026) ($MN)
      • TABLE 69     APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 70     APAC ABLATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 71     APAC EMBOLIZATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 72     APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 73     APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 74     ROW INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
      • TABLE 75     ROW ABLATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 76     ROW EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 77     ROW EMBOLIZATION MARKET REVENUE, BY PROCEDURE, (2018-2026) ($MN)
      • TABLE 78     ROW INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 79     ROW ABLATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 80     ROW EMBOLIZATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 81     ROW INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 82     ROW INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 83     PRODUCT APPROVAL (2017-2019)
      • TABLE 84     ACQUISITION AND PARTNERSHIP (2017-2020)
      • TABLE 85     NEW PRODUCT LAUNCH (2017-2019)
      • TABLE 86     OTHERS (2017-2019)
      • TABLE 87     ANGIODYNAMICS, INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 88     ANGIODYNAMICS, INC.: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 89     ANGIODYNAMICS, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 90     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 91     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 92     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 93     GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 94     GUERBET: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 95     GUERBET: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 96     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 97     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 98     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 99     MEDTRONIC PLC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 100     MEDTRONIC PLC:TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 101     MEDTRONIC PLC: MINIMALLY INVASIVE THERAPIES GROUP REVENUE, BY SUB-SEGMENT, (2017-2019) ($MN)
      • TABLE 102     MEDTRONIC PLC:TOTAL REVENUE, BY GEOGRAPHY, (20167-2019) ($MN)
      • TABLE 103     MERIT MEDICAL SYSTEM, INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 104     MERIT MEDICAL SYSTEM, INC: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 105     MERIT MEDICAL SYSTEM, INC: TOTAL REVENUE, BY CARDIVASCULAR SUB-SEGMENT, (2017-2019) ($MN)
      • TABLE 106     MERIT MEDICAL SYSTEM, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 107     TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 108     TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 109     TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 110     VARIAN MEDICAL SYSTEM INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 111     VARIAN MEDICAL SYSTEM INC.: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 112     VARIAN MEDICAL SYSTEM INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)

      LIST OF FIGURES

      • FIGURE 1     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: INTERVENTIONAL ONCOLOGY GLOBAL MARKET
      • FIGURE 3     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     INTERVENTIONAL ONCOLOGY CLINICAL TRIAL (2018-2019)
      • FIGURE 9     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     INTERVENTIONAL ONCOLOGY: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 12     ABLATION GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 13     EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 14     ABLATION DEVICES NUMBER OF UNITS, BY PRODUCT TYPE, (2018-2026) (NO’S)
      • FIGURE 15     RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BY REGION (2019) (NO’S)
      • FIGURE 16     MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BY REGION (2019) (NO’S)
      • FIGURE 17     CRYOABLATION DEVICES NUMBER OF UNITS, BY REGION (2019) (NO’S)
      • FIGURE 18     LIVER, KIDNEY, LUNG, PROSTATE, BRAIN & SPINE CANCER MARKET PENETRATION IN INTERVENTIONAL ONCOLOGY GLOBAL MARKET, 2019 (%)
      • FIGURE 19     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BY PRODUCT (2019 V/S 2026) (%)
      • FIGURE 20     ABLATION GLOBAL MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 21     EMBOLIZATION GLOBAL MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 22     EMBOLIZATION GLOBAL MARKET SHARE, BY PROCEDURE (2019 V/S 2026) (%)
      • FIGURE 23     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 24     ABLATION GLOBAL MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 25     EMBOLIZATION GLOBAL MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 26     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
      • FIGURE 27     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN), CAGR (%)
      • FIGURE 28     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BY GEOGRAPHY (2019) (%)
      • FIGURE 29     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 30     NORTH AMERICA EMBOLIZATION MARKET SHARE, BY PROCEDURE (2019 V/S 2026) (%)
      • FIGURE 31     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SHARE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 32     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 33     NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 34     U.S. INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 35     U.S. EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 36     U.S. INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 37     U.S. INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 38     REST OF NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 39     REST OF NORTH AMERICA EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 40     REST OF NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 41     REST OF NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 42     EUROPE INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 43     EUROPE EMBOLIZATION MARKET SHARE, BY PROCEDURE (2019 V/S 2026) (%)
      • FIGURE 44     EUROPE INTERVENTIONAL ONCOLOGY MARKET SHARE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 45     EUROPE INTERVENTIONAL ONCOLOGY MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 46     EUROPE INTERVENTIONAL ONCOLOGY MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 47     GERMANY INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 48     GERMANY EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 49     GERMANY INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 50     GERMANY INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 51     FRANCE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 52     FRANCE EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 53     FRANCE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 54     FRANCE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 55     ITALY INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 56     ITALY EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 57     ITALY INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 58     ITALY INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 59     REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 60     REST OF EUROPE EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 61     REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 62     REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 63     APAC INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 64     APAC EMBOLIZATION MARKET SHARE, BY PROCEDURE (2019 V/S 2026) (%)
      • FIGURE 65     APAC INTERVENTIONAL ONCOLOGY MARKET SHARE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 66     APAC INTERVENTIONAL ONCOLOGY MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 67     APAC INTERVENTIONAL ONCOLOGY MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 68     CHINA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 69     CHINA EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 70     CHINA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 71     CHINA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 72     JAPAN INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 73     JAPAN EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 74     JAPAN INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 75     JAPAN INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 76     AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 77     AUSTRALIA EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 78     AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 79     AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 80     REST OF APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 81     REST OF APAC EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 82     REST OF APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 83     REST OF APAC INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 84     ROW INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
      • FIGURE 85     ROW EMBOLIZATION MARKET SHARE, BY PROCEDURE (2019 V/S 2026) (%)
      • FIGURE 86     ROW INTERVENTIONAL ONCOLOGY MARKET SHARE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 87     ROW INTERVENTIONAL ONCOLOGY MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 88     ROW INTERVENTIONAL ONCOLOGY MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
      • FIGURE 89     BRAZIL INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 90     BRAZIL EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 91     BRAZIL INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 92     BRAZIL INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 93     REST OF LATAM INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 94     REST OF LATAM EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 95     REST OF LATAM INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 96     REST OF LATAM INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 97     MIDDLE EAST & OTHERS INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY PRODUCT, ABLATION AND EMBOLIZATION MARKET REVENUE, BY PRODUCT TYPE (2019 V/S 2026) ($MN)
      • FIGURE 98     MIDDLE EAST & OTHERS EMBOLIZATION MARKET REVENUE, BY PROCEDURE (2019 V/S 2026) ($MN)
      • FIGURE 99     MIDDLE EAST & OTHERS INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY APPLICATION, ABLATION AND EMBOLIZATION MARKET REVENUE, BY APPLICATION (2019 V/S 2026) ($MN)
      • FIGURE 100     MIDDLE EAST & OTHERS INTERVENTIONAL ONCOLOGY MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 101     KEY GROWTH STRATEGIES, (2017-2020)
      • FIGURE 102     SWOT: ANGIODYNAMICS, INC.
      • FIGURE 103     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 104     SWOT: GUERBET
      • FIGURE 105     SWOT: JOHNSON & JOHNSON
      • FIGURE 106     SWOT: MEDTRONIC PLC
      • FIGURE 107     SWOT: MERIT MEDICAL SYSTEM, INC.
      • FIGURE 108     SWOT: MONTERIS MEDICAL
      • FIGURE 109     SWOT: SIRTEX MEDICAL
      • FIGURE 110     SWOT: TERUMO CORPORATION
      • FIGURE 111     SWOT: VARIAN MEDICAL SYSTEM INC.

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABK BIOMEDICAL INC.
      • 2     ANGIODYNAMICS, INC.
      • 3     BOSTON SCIENTIFIC CORPORATION
      • 4     CLINICAL LASERTHERMIA SYSTEMS
      • 5     DELCATH SYSTEMS, INC
      • 6     ERBE ELKTROMEDIZIN GMBH
      • 7     GUERBET
      • 8     ICECURE MEDICAL
      • 9     IMBIOTECHNOLOGIES
      • 10     JOHNSON & JOHNSON
      • 11     MEDTRONIC PLC
      • 12     MEDWAVES MEDICAL
      • 13     MERIT MEDICAL SYSTEM
      • 14     MISONIX
      • 15     MONTERIS MEDICAL INC
      • 16     PROFOUND MEDICAL CORP.
      • 17     ROYAL PHILLIPS
      • 18     SANARUS MEDICAL
      • 19     SIRTEX MEDICAL LIMITED
      • 20     SONACARE MEDICAL LLC
      • 21     TERUMO CORPORATION
      • 22     TROD MEDICAL
      • 23     VARIAN MEDICAL SYSTEM